Subscriber access provided by READING UNIV
Article
Gastrodin and Isorhynchophylline Synergistically Inhibit MPP+induced Oxidative Stress in SH-SY5Y Cells by Targeting ERK1/2 and GSK-3# Pathways: Involvement of Nrf2 Nuclear Translocation Qiang Li, Chengu Niu, Xiaojie Zhang, and Miaoxian Dong ACS Chem. Neurosci., Just Accepted Manuscript • DOI: 10.1021/acschemneuro.7b00247 • Publication Date (Web): 08 Nov 2017 Downloaded from http://pubs.acs.org on November 10, 2017
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
ACS Chemical Neuroscience is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 54
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
1 2
Gastrodin and Isorhynchophylline Synergistically Inhibit MPP+-induced
3
Oxidative Stress in SH-SY5Y Cells by Targeting ERK1/2 and GSK-3β Pathways:
4
Involvement of Nrf2 Nuclear Translocation
5 6
Authors: Qiang Li,† Chengu Niu,§ Xiaojie Zhang,†
,
‡
and Miaoxian Dong*, †
,
‡
7 8
Authors’ Affiliations: † The Institute of Medicine, Qiqihar Medical University, Qiqihar
9
161006, China. §Department of Hematology, the First Affiliated Hospital, Harbin
10
Medical University, Harbin 150001, China.
11 12
‡
M.X. Dong and X.J. Zhang shared senior authorship
13 14
Running title: GAS/IRN facilitates Nrf2 nuclear accumulation
15 16 17 18 19 20 21 22 23 24 25 1
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
ABSTRACT
2 3
Recently, the pathogenesis of Parkinson’s disease (PD) is multifactorial event.
4
Combination therapies might be more effective in controlling the disease. Thus, the
5
studies reported were designed to test the hypothesis that gastrodin (GAS)-induced de
6
novo synthesis of nuclear factor E2-related factor 2 (Nrf2) and isorhynchophylline
7
(IRN) inhibition of Nrf2 nuclear export contribute to their additive or synergistic
8
neuroprotective effect. Here, we have demonstrated that the combination of GAS and
9
IRN (GAS/IRN) protect SH-SY5Y cells against 1-methyl-4-phenylpyridinium (MPP+)
10
toxicity in a synergistic manner. Concomitantly, GAS/IRN led to a statistically
11
significant reduction of oxidative stress, as assessed by reactive oxygen species (ROS)
12
and lipid hydroperoxides (LPO), and enhancement of both glutathione (GSH) and
13
thioredoxin (Trx) systems compared with treatment with either agent alone in
14
MPP+-challenged SH-SY5Y cells. Interestingly, GAS but not IRN activated
15
extracellular signal-regulated kinases 1 and 2 (ERK1/2), leading to a increase in de
16
novo synthesis of Nrf2 and nuclear import of Nrf2. Simultaneously, IRN but not GAS
17
suppressed both constitutive glycogen synthase kinase (GSK)-3β and Fyn activation,
18
which inhibited nuclear export of Nrf2. Importantly, simultaneous inhibition of
19
GSK-3β pathway by IRN and activation of ERK1/2 pathway by GAS synergistically
20
induced accumulation of Nrf2 in the nucleus in SH-SY5Y cells challenged with MPP+.
21
Furthermore, the activation of the ERK1/2 pathway and inhibition of GSK-3β
22
pathway by GAS/IRN are mediated by independent mechanisms. Collectively, these
23
novel findings suggest an in vitro model of synergism between IRN and GAS in the
24
induction of neuroprotection warrant further investigations in vivo.
25
2
ACS Paragon Plus Environment
Page 2 of 54
Page 3 of 54
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
1
KEYWORDS:
2 3
Gastrodin; Isorhynchophylline; Synergism; Parkinson’s disease; Nuclear factor
4
E2-related factor 2
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
3
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
INTRODUCTION
2 3
Parkinson’s disease (PD) is a neurodegenerative disease with the major pathology
4
being the progressive loss of dopaminergic neurons in the substantia nigra resulting in
5
dopamine deficiency in the striatum [1]. Pharmacological remedies targeting the
6
dopaminergic network are relatively effective at ameliorating symptoms [2]. Despite
7
the increasing knowledge regarding the pathomechanism [3], no effective
8
disease-modifying therapy is yet available to combat PD [4]. In this context, the need
9
to find novel strategies to counteract neurodegenerative progression is becoming
10
increasingly clear [5].
11 12
Although several biochemical and genetic defects have been identified [6], oxidative
13
stress is widely considered as a central event in the progression of the pathology,
14
either as a cause or effect of PD [7]. Excessive reactive oxygen species (ROS) can
15
lead to dopaminergic neuron vulnerability and eventual death [8]. Antioxidant
16
remedies, particularly herbal antioxidants, show promise to delay or prevent the
17
disease [9]. Nuclear factor E2-related factor 2 (Nrf2) plays a critical role in regulating
18
cellular defense against oxidative stress by activating the expression of an array of
19
antioxidant response element (ARE)-dependent genes [10]. Studies demonstrate that
20
Nrf2 knockout mice are hypersensitive to PD-causing toxins [11], whereas Nrf2
21
over-expression either through pharmacological activation or by genetic means
22
renders a neuroprotective response [12, 13].
23 24
Even though information of phosphorylation at the exact residue(s) of Nrf2 protein by
25
activated extracellular signal-regulated kinases 1 and 2 (ERK1/2) is still lacking [14], 4
ACS Paragon Plus Environment
Page 4 of 54
Page 5 of 54
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
1
unequivocal evidence indicates that ERK1/2 is a positive regulator of Nrf2 nuclear
2
accumulation stimulating ARE activation [15]. On the contrary, Fyn kinase can
3
directly phosphorylate Nrf2 protein at Tyr-568 and promote its nuclear exclusion, and
4
consequently contributing to the suppression of ARE-mediated gene expression [16].
5
Glycogen synthase kinase (GSK)-3β acts as an upstream kinase of Fyn that
6
contributes to Nrf2 phosphorylation [17].
7 8
Throughout the history of drug discovery and development, plants have been an
9
important source for the discovery of novel therapeutically active compounds for
10
neurodegenerative diseases [18]. In previous work, we have demonstrated that
11
gastrodin (GAS) prevents motor deficits in 1-methyl-4-phenyl-1,2,3,6-
12
tetrahydropyridine (MPTP)-intoxicated mice via ERK1/2-Nrf2 pathway and that
13
isorhynchophylline (IRN) blocks 1-methyl-4-phenylpyridinium (MPP+)-induced
14
oxidative stress in vitro [19]. The complexity of the molecular-biological mechanisms
15
for PD requires multi-target therapeutics [20]. A cocktail of agents is a promising
16
method in search for new drugs for PD. Does GAS acts synergistically with IRN to
17
promote translocation of Nrf2 into the nucleus and, if so, what would be the signaling
18
pathway involved in synergistic action? To address these questions we hypothesized
19
that GAS-mediated nuclear import of Nrf2 and IRN inhibition of Nrf2 nuclear
20
exclusion contribute to synergistic neuroprotective effect by combinations of IRN and
21
GAS, hereafter referred to as GAS/IRN. Results in this report support our hypothesis.
22 23 24 25
5
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1 2
RESULTS AND DISCUSSION
3
GAS/IRN can synergistically protect SH-SY5Y cells against MPP+ toxicity by
4
attenuation of oxidative stress
5 6
Consistent with our previous observations, IRN or GAS alone exhibited a
7
concentration-dependent neuroprotective action [21, 22]. Combined treatment with
8
GAS and IRN at a constant concentration ratio of 10 to 3 substantially improved the
9
viability of SH-SY5Y cells challenged with MPP+, compared with the cells treated
10
with IRN or GAS alone, as shown by the 3-(4,5-dimethylthiazol-2-yl)-5-
11
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- tetrazolium, inner salt (MTS) assay
12
(Figure 1A). Calculation of combination index (CI) with CompuSyn software
13
revealed that the interaction of GAS and IRN is highly synergistic (Table 1).
14
Specifically, the maximal synergism was found when 0.3 µM IRN was combined with
15
1 µM GAS, therefore we selected them for further synergistic mechanism studies.
16
Again, cell proliferation ELISA BrdU colorimetric assay showed that combination of
17
GAS with IRN synergistically stimulate cell proliferation in MPP+-challenged
18
SH-SY5Y cells (Supplemental Table S1 and Supplemental Figure S1, available at
19
http://pubs.acs.org as Supporting Information), suggesting that promotion of
20
proliferation by GAS/IRN may contribute to their inhibitory action on MPP+-induced
21
death of SH-SY5Y cells. Moreover, combination treatment of GAS with IRN showed
22
the greatest increase in cell viability compared to monotherapy with GAS in
23
SH-SY5Y cells exposed to Aβ25-35, as shown by MTS assay (Supplemental Table S2
24
and Supplemental Figure S2, available at http://pubs.acs.org as Supporting
25
Information). Similar, inhibitory effects on MPP+-induced death of SH-SY5Y cells
26
were produced by Nrf2 activator tertiary butylhydroquinone (tBHQ) (Supplemental 6
ACS Paragon Plus Environment
Page 6 of 54
Page 7 of 54
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
1
Figure S3, available at http://pubs.acs.org as Supporting Information). Short hairpin
2
RNA (shRNA)-mediated knockdown of Nrf2 abolished IRN and/or GAS-mediated
3
neuroprotection against MPP+-induced toxicity in SH-SY5Y cells (Figure 1B), hinting
4
a role of its antioxidant properties. As shown in Figure 1C and D, treatment with IRN
5
or GAS alone resulted in modest reduction in both ROS production and LPO level in
6
MPP+-challenged SH-SY5Y cells, and these reductions were further aggravated when
7
IRN was combined with GAS, suggesting that antioxidant properties of GAS/IRN
8
may contribute to their neuroprotective effects.
9 10
Research into historical literatures have revealed that Uncaria rhynchophylla (UR)
11
and Gastrodia elata Blume (GE) are usually used in combination to treat tremor
12
syndrome in traditional Chinese medicine through antioxidant mechanisms. IRN and
13
GAS are two antioxidant compounds found in UR and GE, respectively [23]. Liu et al.
14
reported that UR in combination with GE exerts strong antioxidant activities [24].
15
Although our knowledge about their bioavailability and pharmacokinetic interactions
16
between IRN and GAS is far from being complete, based on the findings from
17
preliminary studies and our previous studes [21, 22], we chose IRN and GAS at a
18
constant concentration ratio of 10 to 3. However, we have used IRN at 0.3 µM and
19
GAS at 1 µM concentrations in this study that should be physiologically attainable in
20
vivo [25, 26].
21 22
In the present study, we chose the SH-SY5Y cell line for specific reasons even though
23
primary cells are more physiologically relevant than immortalized cell lines. First,
24
primary neurons do not maintain cell division in culture and are in heterogeneous
25
states of neurodifferentiation. Second, SH-SY5Y cell are more amenable to high level 7
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
transduction than primary neurons. Third, very large amounts of cells in our present
2
study are required which is difficult to achieve with primary neurons. However,
3
SH-SY5Y cells share the limitations common to in vitro experimental models, namely
4
an inability to assess glial-neuronal-endothelial interactions, pharmacokinetic
5
properties, and related issues of bioavailability, dose, and bioeffective concentrations.
6
All these factors mean that it is difficult to extrapolate relevant in vivo concentrations
7
of GAS and/or IRN from in vitro results, and typically, the concentrations required for
8
a given effect in vitro will be higher than those required for parallel effects in vivo.
9
Further studies are necessary to evaluate antioxidant properties of GAS and/or IRN in
10
vivo in the context of PD-related neurotoxin.
11 12
The complex pathophysiological mechanisms involved in the etiology of PD limit the
13
discovery of agents to modify its course [27]. Some findings suggest, although do not
14
prove, that GAS and IRN alone have exhibited possible preventive and therapeutic
15
effects on PD [28, 29]. The key new finding made in our present study is that GAS
16
and IRN exert neuroprotection in a synergistic fashion, suggesting that multi-targeting
17
strategy with plant-derived compounds combination achieves a disease-modifying
18
effect in PD. Although antioxidant therapy is unlikely to provide a panacea against
19
neurodegenerative diseases, wide varieties of antioxidants show promise to delay or
20
prevent PD [9]. Plants have their own natural antioxidants to protect their structures
21
against ROS produced during photosynthesis [30]. Single plant-derived antioxidant
22
often does not enabled to reach the therapeutic threshold [31]. Combination therapy
23
has the potential to reduce single-agent therapeutic dose and to increase therapeutic
24
efficacy [20]. In the current study, although both GAS and IRN individually exhibit
25
antioxidant properties, when combined, they synergistically inhibit oxidative stress 8
ACS Paragon Plus Environment
Page 8 of 54
Page 9 of 54
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
1
evoked by MPP+. This finding suggests that these two agents may work through
2
independent mechanism to protect against MPP⁺-induced oxidative damage. The
3
significance of the antioxidant properties reported herein will be substantially clearer
4
if it is known whether GAS/IRN, administered in vivo, crosses the blood-brain barrier.
5 6
GAS/IRN enhances thioredoxin and GSH antioxidant systems in
7
MPP+-challenged SH-SY5Y cells
8 9
GSH and Trx systems are essential for neuronal antioxidant defense [32]. Thus, the
10
next question is whether GSH antioxidant systems are regulated following IRN and/or
11
GAS treatment. As depicted in Figure 2A, IRN and/or GAS, as expected, enhanced
12
GSH concentration in MPP+-challenged SH-SY5Y cells. GAS/IRN showed the
13
greatest efficacy in increasing GSH concentration compared to IRN or GAS alone.
14
Again, GSH/GSSG ratio revealed a similar result. As illustrated in Figure 2B, C, and
15
D, the data from the western blot and PCR analyses indicated that catalytic subunits
16
from glutamate cysteine ligase (GCLc) expression at levels of transcription and
17
translation in MPP+-challenged SH-SY5Y cells treated with GAS/IRN was higher
18
than those treated with IRN or GAS alone. GSH-Px activity in MPP+-challenged
19
SH-SY5Y cells in the response to IRN and/or GAS showed similar trends (Figure 2E),
20
whereas the mRNA and protein expression of modulatory subunits from glutamate
21
cysteine ligase (GCLm) remained unchanged. Alongside, GAS alone or the GAS/IRN
22
significantly increased SOD levels, whereas IRN alone failed to do so (Supplemental
23
Figure S4, available at http://pubs.acs.org as Supporting Information).
24 25
A causal role for GSH depletion in PD is supported by both clinical and animal 9
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
studies [33, 34]. The present study demonstrates that MPP+ increase oxidative stress
2
and result in marginally, if at all, increased GCLc expression, which acts as an
3
antioxidant adaptive response to oxidative stress in SH-SY5Y cells. GAS and IRN
4
synergistically enhance GSH system that may contribute to GAS/IRN-mediated
5
neuroprotection. Poor penetration through the blood brain barrier represents a major
6
challenge to be overcome in GSH clinical application [35]. Therefore, induction of de
7
novo GSH synthesis in brain may be a potential therapeutic strategy against PD.
8 9
Because the Trx system represents an important target for PD therapy [36], we were
10
prompted to investigate whether IRN and/or GAS was also capable of activates Trx
11
system. As illustrated in Figure 3A, B and C, TrxR enzymes activity and Trx1 protein
12
expression were increased in MPP+-challenged SH-SY5Y cells in response to IRN or
13
GAS alone, and this elevation was further enhanced when IRN was combined with
14
GAS. Specifically, real-time- PCR of Trx1 and TrxR revealed a similar result (Figure
15
3D). IRN and/or GAS markedly attenuated MPP+-induced both reduction of NAD+
16
and NAD+/NADH ratio. GAS/IRN seemed to enhance increase of NAD+ and
17
NAD+/NADH ratio to a greater extent compared with IRN or GAS alone (Figure 3E).
18 19
Intracellular Trx1 exerts most of its antioxidant properties in the presence of TrxR and
20
NADPH through scavenging of ROS [37]. Studies have shown that Trx1 protects
21
neurons against the oxidative stress and damage caused by the PD-related neurotoxin
22
[38]. The present study demonstrates that MPP+-induced adaptive activation of Trx
23
system is enhanced by GAS and/or IRN. Thus, it is possible that GAS and IRN share
24
Trx system for its antioxidant properties, but differ in their upstream signals. All of
25
these findings support the notion that inhibition of oxidative stress by GAS/IRN in 10
ACS Paragon Plus Environment
Page 10 of 54
Page 11 of 54
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
1
MPP+-challenged SH-SY5Y cells might be at least partially mediated by the
2
activation of Trx system. In addition, our findings must be interpreted in the context
3
of certain limitations. This current report focused on the effect of GAS and/or IRN on
4
GSH system and Trx system. Additional experiments are necessary to evaluate the
5
role of GAS and/or IRN in regulating activity of any other antioxidant enzymes.
6 7
GAS/IRN activates the Nrf2-ARE antioxidant system in SH-SY5Y cells
8
challenged with MPP+
9 10
Emerging evidence indicates that transcription of a variety of antioxidant genes
11
through cis-acting sequence known as ARE plays a crucial role in providing
12
cytoprotection against pro-oxidant stimuli [39]. Thus, we tested if IRN and/or GAS
13
induce activation of the ARE. As shown in Figure 4A, GAS/IRN yielded significantly
14
greater ARE-mediated luciferase activity than IRN or GAS alone in MPP+-challenged
15
SH-SY5Y cells. In parallel, we tested whether IRN and/or GAS stimulates
16
translocation of Nrf2 into the nucleus and found that ability of nuclear translocation of
17
Nrf2 also significantly potentiated by the combination treatment when compared with
18
IRN or GAS alone (Figure 4B and C). These findings were also confirmed by
19
ELISA-based TransAM™ Nrf2 (Supplemental Figure S5, available at
20
http://pubs.acs.org as Supporting Information). However, our PCR results, which are
21
not consistent with the results of western blot, were contrary to our initial expectation.
22
We observed that GAS alone or in combination with IRN up-regulated Nrf2 mRNA
23
expression in MPP+-challenged SH-SY5Y cells, while IRN alone have little effect
24
(Figure 4D). Given that Bach1 competes with Nrf2 for binding to the ARE in the
25
phase II antioxidant enzymes promoter [40], and Keap1 can assemble with the Cul3 11
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
protein to form a Cullin-RING E3 ligase complex for the degradation of Nrf2 [41], we
2
examined whether IRN and/or GAS might modulate Bach1 and Keap1 protein
3
expression. However, a slight but not significant alteration of both Bach1 and Keap1
4
expression due to IRN and/or GAS could also be observed in MPP+-challenged
5
SH-SY5Y cells (Figure 4E).
6 7
GAS but not IRN activates ERK1/2, an upstream regulator of Nrf2 nuclear
8
translocation, in MPP+-challenged SH-SY5Y cells
9 10
Increasing evidence suggests that MAPKs are implicated in the regulation of
11
ARE-driven gene transcription, in which ERK1/2 and JNK are positive regulators
12
while p38MAPK is a negative regulator [42]. This led us to hypothesize that GAS
13
and/or IRN-mediated ERK1/2 activation stimulates translocation of Nrf2 into the
14
nucleus. Using an ELISA-based technique, nuclear extracts from the SH-SY5Y cells
15
were assessed for the ability of host transcription factors to bind to their respective
16
DNA sequences. Figure 5A depicts a marginal increase in ATF-2, c-Jun, and c-Myc
17
levels in response to MPP+. GAS but not IRN dramatically increases ATF-2, c-Jun,
18
and c-Myc levels in MPP+-challenged SH-SY5Y cells, but did not significantly affect
19
the levels of MEF2 and STAT1. These results suggest that GAS increases MAPK
20
activation in MPP+-challenged SH-SY5Y cells. These observations were verified by
21
western blotting analyses and found that GAS but not IRN induced phosphorylation
22
of ERK1/2, but not of p38MAPK or JNK, which support our hypotheses (Figure 5B and
23
C). Noteworthy, quantitative analysis of ERK1/2 phosphorylation showed a trend but
24
not a statistically significant elevation in IRN/GAS-treated treatment versus GAS
25
alone-treatment in MPP+-challenged SH-SY5Y cells, possibly because of higher 12
ACS Paragon Plus Environment
Page 12 of 54
Page 13 of 54
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
1
variability. In contrast to the complete block of Nrf2 mRNA expression, a dominant
2
negative (DN) mutant of ERK2 only partially attenuated GAS/IRN-induced nuclear
3
localization of Nrf2 (Figure 5D, E, and F). Blocking GSK-3β by LiCl partially
4
attenuated GAS/IRN-mediated nuclear localization of Nrf2, whereas the mRNA
5
levels of Nrf2 were unaffected by LiCl. These data hint that nuclear export
6
mechanism involved in nuclear accumulation of Nrf2 mediated by GAS/IRN.
7 8
Considering the complexity of the antioxidant system, it seems reasonable to consider
9
that the induction of endogenous protective pathways, such as the Nrf2-ARE pathway,
10
is a viable strategy for inhibiting oxidative stress [43]. Recent evidence suggests that
11
direct phosphorylation of Nrf2 by ERK1/2 has only a slight effect on Nrf2
12
translocation. ERK1/2 activation also can lead to phosphorylation of Bach1 blocking
13
the Nrf2 activity [44]. It is more effective in controlling oxidative stress to
14
simultaneously engage nuclear import and nuclear export of Nrf2 through
15
combination therapies [45]. In the current study, GAS but not IRN was shown to
16
increase the phosphorylation of ERK1/2, and then Nrf2 are de novo synthesized and
17
imported in the nucleus. However, no regulatory effect of GAS/IRN on Bach1 and
18
Keap1, two negative regulators of Nrf2, could be observed. Our results also found that
19
the ERK1/2, but not JNK and p38MAPK, plays a major role in the GAS/IRN- mediated
20
nuclear accumulation of Nrf2. These data suggest that ERK1/2 is essential, but not
21
sufficient, for nuclear accumulation of Nrf2.
22 23
IRN but not GAS inhibits constitutive phosphorylation of GSK-3β and Fyn in
24
MPP+-challenged SH-SY5Y cells
25
13
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
Mounting evidence suggests that Fyn kinase can directly phosphorylate Nrf2 at
2
Tyr-568 and promote its nuclear exclusion and degradation [46]. Thus, we assumed
3
that IRN and/or GAS might decrease the level of Fyn phosphorylation, inhibiting
4
nuclear exclusion of Nrf2. Western blot experiments presented in Figure 6A and B
5
indicate that IRN, but not GAS, inhibits Fyn phosphorylation in MPP+-challenged
6
SH-SY5Y cells. Pretreatment with GSK-3βinhibitor LiCl abrogated
7
GAS/IRN-mediated Fyn phosphorylation. GSK-3β acts as an upstream kinase of Fyn
8
that promotes Nrf2 nuclear exclusion [47]. In our experimental paradigm, we were
9
interested in ascertaining whether GSK-3β inactivation occurred in response to IRN
10
and/or GAS. As shown by western blotting analyses, IRN, but not GAS, suppresses
11
GSK-3β phosphorylation at Tyr-297 (that is, inactivation), while GAS was slightly
12
but not significantly enhanced GSK-3β phosphorylation in MPP+-challenged
13
SH-SY5Y cells. Importantly, IRN and GAS/IRN produced similar inhibitory effects
14
on GSK-3β phosphorylation at Tyr-297 in MPP+-challenged SH-SY5Y cells. Fyn
15
shRNA did not change GSK-3β phosphorylation by GAS/IRN suggest, although do
16
not prove, that GSK-3β is an upstream kinase for threonine phosphorylation of Fyn
17
(Figure 6C and D). Notably, Akt phosphorylation is apparently not affected by GAS
18
or/and IRN in MPP+-challenged SH-SY5Y cells, indicating that the
19
GAS/IRN-mediated GSK-3β dephosphorylation at Tyr-297 do not result from Akt
20
activation (Supplemental Figure S6A and S6B, available at http://pubs.acs.org as
21
Supporting Information).
22 23
Fyn phosphorylates Nrf2 protein at tyrosine 568 and promotes its nuclear export and
24
degradation [16]. GSK-3β acts upstream of Fyn, and activates its phosphorylation and
25
resulting in its nuclear localization [17]. Having accumulated in the nucleus Fyn 14
ACS Paragon Plus Environment
Page 14 of 54
Page 15 of 54
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
1
kinase directly phosphorylate Nrf2 [48]. Our results demonstrated for the first time
2
evidence that in SH-SY5Y cells, IRN, or GAS/IRN, but not GAS, can suppress
3
GSK-3β-dependent Fyn phosphorylation, which, in turn, resulted in a marked
4
reduction nuclear exclusion of Nrf2. Levels of phospho-GSK-3β at Tyr-297 and
5
phospho-Fyn correlate with their activation status. Another important finding of this
6
study is that GSK-3β acts as an upstream kinase of Fyn, as supported by the
7
observation that GSK-3β inhibition by LiCl blocked the ability of GAS/IRN to oppose
8
Fyn phosphorylation.
9 10
Activation of the ERK1/2 and inactivation of GSK-3β by GAS/IRN is mediated
11
by independent mechanisms
12 13
The available evidence, albeit limited, is highly suggestive that crosstalk between
14
ERK1/2 and GSK-3β signaling pathways regulate ARE-driven gene transcription [49].
15
As depicted in Figure 7A, inhibition of either ERK1/2 or GSK-3β only partially
16
reversed
17
simultaneous inhibition of these two pathways almost completely abrogated ARE
18
activation induced by GAS/IRN. This additive effect suggested that ERK1/2 and
19
GSK-3β might be involved in the parallel ARE activation pathway rather than in the
20
same pathways. An ERK kinase assay presented in Figure 7B and C indicate that
21
phosphorylate Elk-1, a major substrate of phospho-ERK, was marginally increased by
22
MPP+ alone treatment, strongly increased by co-treatment with MPP+ and GAS/IRN.
23
These results suggest that ERK1/2 activation by GAS/IRN are independent of
24
GSK-3β pathway, as phosphorylation of Elk-1 is parallel to ERK1/2 activation. As
25
shown in the western blot analysis in Figure 7D and E, GAS/IRN-mediated Fyn
the
GAS/IRN-induced
ARE-dependent
luciferase
15
ACS Paragon Plus Environment
activity,
while
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
dephosphorylation was not altered by ERK1/2 inhibitor PD 98059, indicating that
2
ERK1/2 and Fyn is two separate and independent pathways involving Nrf2 nuclear
3
accumulation. Blocking ERK1/2 by dominant-negative mutation, shRNA-based Fyn
4
knockdown, or shRNA-based GSK-3β knockdown significantly reduced, while
5
shRNA-based Nrf2 knockdown almost completely block, the ROS-scavenging effect
6
of GAS/IRN in MPP+-challenged SH-SY5Y cells (Figure 7F).
7 8
We showed that inhibition of both the ERK1/2 or GSK-3β pathways partially reversed
9
the GAS/IRN-induced accumulation of Nrf2 in the nucleus, which is completely
10
reversed by the simultaneous inhibition of these two pathways. Inhibition of GSK-3β
11
by LiCl failed to alter GAS/IRN-induced ERK1/2 phosphorylation. PD98059 also had
12
no effect on GAS/IRN-induced GSK-3β phosphorylation. This finding suggests that
13
ERK1/2 and GSK-3β is independent pathways regulating Nrf2 nuclear accumulation.
14 15
The available evidence in humans, albeit limited, is highly suggestive that two key
16
amino acid resiudes (Ser40 and Tyr568) may regulate Nrf2 localization through
17
phosphorylation [50]. Alteration of Nrf2 phosphorylation at Ser40 and/or Tyr568 in
18
the response to GAS and/or IRN should hence be investigated when proper tools such
19
as monoclonal antibodies will be available to establish their possible role in GAS
20
and/or IRN-induced Nrf2 nuclear translocation. Although the methodology we used to
21
determine the GSK-3β activation has certain limitations, it is conceivable that the
22
inhibiting Nrf2 nuclear exclusion can be attributed to the IRN inhibition of
23
constitutive GSK-3β activation.
24 25
The key findings made in our present study are that GAS and IRN exert synergistic 16
ACS Paragon Plus Environment
Page 16 of 54
Page 17 of 54
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
1
neuroprotective effect in an in vitro models induced by PD-related neurotoxin.
2
GAS/IRN-mediated synergistic neuroprotection is most likely to be attributable to its
3
antioxidant properties by dual-promoting Trx and GSH systems. This may be
4
mediated through two complementary pathways: (i) ERK1/2-dependent de novo
5
synthesis of Nrf2, and (ii) GSK-3β-dependent suppression of Nrf2 nuclear exclusion.
6
Our findings lend strong support to our hypothesis as expected.
7 8
Based on our observations, a schematic diagram illustrating putative mechanism
9
whereby GAS/IRN protects against MPP+-induced SH-SY5Y cells oxidative stress is
10
presented in Figure 8. IRN blocks nuclear exclusion of Nrf2 by reducing Fyn
11
phosphorylation, which is mediated by inhibition of GSK-3β activation. In addition,
12
GAS activated ERK1/2, which also enhanced de novo synthesis of Nrf2 and its
13
nuclear translocation. GAS/IRN-mediated Nrf2 nuclear accumulation induces
14
ARE-driven gene transcription and attenuates oxidative stress in vitro. Nevertheless,
15
the underlying mechanisms are certainly more complex than it is described here.
16
Whether both de novo synthesis of Nrf2 and inhibition of its nuclear export are
17
sufficient to explain synergistic neuroprotection by GAS/IRN remains unclear.
18
Therefore, these data suggest that an in vitro model of synergism between IRN and
19
GAS in the induction of neuroprotection warrant further investigations in vivo.
20 21 22 23 24 25
17
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
METHODS
2 3
Cell culture and treatment paradigm
4 5
Human neuroblastoma cells (SH-SY5Y) were purchased from the Shanghai Institute
6
of Cell Biology (Shanghai, China) and grown in Dulbecco’s Modified Eagle’s
7
Medium (DMEM) supplemented with 10% (v/v) heat-inactivated fetal bovine serum
8
and 1% penicillin-streptomycin maintained at 37 °C in a humidified atmosphere of 5%
9
CO2 and 95% air. SH-SY5Y cells were never cultivated beyond passage 20. For
10
neuronal differentiation of SH-SY5Y cells, retinoic acid (RA) was added a day after
11
plating at final concentration 10 ߤM and maintained for 3 days as previously
12
described [51]. SH-SY5Y cells were treated with 1 µM GAS (98% purity by HPLC;
13
Jingzhu Bio-Technology Co., Ltd, Nanjing, China), 0.3 µM IRN (98% purity by
14
HPLC; Jingzhu), GAS plus IRN, or tBHQ (98% purity by HPLC; Sigma-Aldrich, St.
15
Louis, MO) for 1 h prior to the challenge with MPP+ (Sigma-Aldrich) at 500 µM or
16
β-amyloid peptide (fragment 25-35; Sigma-Aldrich) in cultured hippocampal neurons.
17
for additional 24 h. For inhibitor studies, the cells were pretreated with or without
18
PD98059 (Sigma), DPI (Sigma), or/and LiCl (Sigma) for 30 min before treatment
19
with or without GAS or/and IRN in the presence or absence of MPP+.
20 21
Analyses of cell viability and proliferation
22 23
A MTS/PMS reagent based CellTiter 96® AQueous Non-Radioactive Cell Proliferation
24
Assay kit (Promega, Madison, WI) was used to quantify the number of viable cells.
25
Cell proliferation was assessed by using a commercially available chemiluminescent 18
ACS Paragon Plus Environment
Page 18 of 54
Page 19 of 54
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
1
cell proliferation ELISA BrdU kit (Roche Applied Science, Mannheim, Germany)
2
according to the protocol provided by the manufacturer.
3 4
Measurement of oxidative stress
5 6
Intracellular ROS levels were determined by oxidative conversion of cell permeable
7
2',7'-dichlorfluorescein-diacetate (DCFH-DA) to DCF using OxiSelect™ Intracellular
8
ROS Assay Kit obtained from Cell Biolabs Inc. (San Diego, CA). The measurement
9
of lipid hydroperoxides (LPO) were performed by using Lipid Hydroperoxide Assay
10
kit, which measures LPO directly utilizing the redox reactions with ferrous ions,
11
purchased from Cayman Chemical Company (Ann Arbor, MI). Glutathione
12
peroxidase (GSH-Px) activity was measured indirectly by a coupled reaction with
13
GSH reductase using Glutathione Peroxidase Assay Kit (Cayman Chemical, MI), and
14
enzyme activity was expressed as the nmol/min/mg of protein. Thioredoxin reductase
15
(TrxR) activity was measured using Thioredoxin Reductase Activity Colorimetric
16
Assay Kit (BioVision Inc, Milpitas, CA). Total intracellular nicotinamide adenine
17
dinucleotide diaphorase (NADH) and NAD+ were measured using the NAD/NADH
18
Quantification Colorimetric Kit (BioVision), and total GSH and oxidized GSH (GSSG)
19
were measured using the GSH/GSSG-Glo™ Assay Kit (Promega). NAD+⁄ NADH
20
ratio and the GSH⁄GSSG ratio were then calculated based on levels of NAD, NADH,
21
GSH and GSSG. Superoxide dismutase (SOD) activity was measured using
22
Superoxide Dismutase Assay Kit (Cayman Chemical). All assays were performed as
23
per the corresponding manufacturer’s protocol.
24 25
Luciferase activity assay 19
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1 2
SH-SY5Y cells were transiently transfected with ARE-containing luciferase reporter
3
plasmid pGL4.37[luc2P/ARE/ Hygro] (Promega) by using FuGENE® 6 Transfection
4
Reagent (Promega), following the protocol provided by the manufacturer. The renilla
5
luciferase reporter plasmid pRL-TK (Promega) was used for standardization of
6
transfection efficiency. At 24 h post-transfection, SH-SY5Y cells were treated as
7
indicated for additional 24 h. After treatment, the cells were lysed and the luciferase
8
activity was measured using a Dual-Glo® Luciferase Assay System (Promega)
9
according to the manufacturer’s instructions. ARE-mediated luciferase activity was
10
expressed as firefly luciferase values normalized to renilla luciferase values.
11 12
Transcription factor activation assay
13 14
The mitogen-activated protein kinase (MAPK) regulated transcription factors ATF-2,
15
c-Myc, STAT1, c-Jun, and MEF2 in the nuclear extracts were measured using an
16
enzyme-linked immunosorbent assay (ELISA)-based TransAM™ MAPK Family
17
Transcription Factor Assay kits (Active Motif Corp., CA) per the manufacturer’s
18
instructions. The color developed, proportional to the amount of specific transcription
19
factor, after adding the HRP substrate was read as optical density units at 450 nm.
20 21
Real-time RT-PCR
22 23
Total RNA was isolated with TRIzol reagent (Invitrogene, Carlsbad, CA). RNA was
24
converted to cDNA by primeScript™ RT reagent kit (Takara Biotechnology, Dalian,
25
China). Real-time PCR was performed using a SYBR® premix Ex Taq™ (Takara) 20
ACS Paragon Plus Environment
Page 20 of 54
Page 21 of 54
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
1
with the following primers: Nrf2, forward primer, 5’-CTT GGC CTC AGT GAT TCT
2
GAA GTG-3’, reverse primer, 5’-CCT GAG ATGG TGA CAA GGG TTG TA-3’;
3
catalytic subunits from glutamate cysteine ligase (GCLc), forward primer, 5’-GAA
4
GTG GAT GTG GAC ACC AGA TG-3’, reverse primer, 5’-TTG TAG TCA GGA
5
TGG TTT GCG ATA A-3’; GCLm, forward primer, 5’-GGA GTT CCC AAA TCA
6
ACC CAG A-3’, reverse primer, 5’-TGC ATG AGA TAC AGT GCA TTC CAA-3’;
7
Trx1, forward primer, 5’-TTG GAC GCT GCA GGT GAT AAA C-3’, reverse primer,
8
5’-GGC ATG GCA TGC ATT TGA CTT CAC ACT C-3’; TxR, forward primer,
9
5’-TAT CAG GAG GGC AGA CTT CAA-3’, reverse primer, 5’- GAC CAT CAC
10
CTT CTT GCC ATA-3’; glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
11
forward primer, 5’-GAA GGT GAA GGT CGG ATG C-3’, reverse primer, 5’-GAA
12
GAT GGT GAT GGG ATT TC-3’. Data were analyzed using the comparative
13
threshold cycle (2-∆∆Ct) method.
14 15
Western blotting analyses
16 17
Nuclear and Cytoplasmic Protein Extraction kit (Beyotime Biotechnology, Haimen,
18
China) was used to fractionate nuclear and cytosolic fractions according to the
19
manufacturer’s instruction. Proteins were separated by SDS-PAGE and transferred
20
onto nitrocellulose membranes, and blotted with antibodies against BTB and CNC
21
homology 1 (Bach1), Nrf2, Keap1, p- c-Jun N-terminal kinases (JNK), p-Fyn, Akt,
22
and p-Akt, which were obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
23
USA), antibodies to Trx1, p-ERK1/2, and p-p38MAPK, which were obtained from Cell
24
Signaling Technology (Beverly, MA, USA), as well as antibodies to GCLc, GCLm,
25
and p-GSK-3β, which were obtained from Abcam Inc. (Cambridge, MA, USA). After 21
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
incubation with peroxidase-conjugated secondary antibodies, membranes were
2
developed with a SuperSignal™ West Pico (Thermo, MA). Equal protein loading was
3
controlled by immunoblot of GAPDH, Lamin B or the corresponding
4
nonphosphorylated species.
5 6
ERK1/2 kinase assay
7 8
ERK1/2 kinase activity assays were performed using nonradioactive kit obtained from
9
Cell Signaling Technology (Beverly, MA) as per the manufacturer’s protocol. Briefly,
10
cell lysates were immunoprecipitated using a monoclonal phospho-ERK1/, then
11
incubated with an Elk-1fusion protein, which allowed precipitated phospho-ERK to
12
phosphorylate Elk-1, a major substrate of p-ERK1/2.
13 14
Adenovirus infection and plasmids transfection
15 16
ERK2 Recombinant Adenovirus (Dominant Negative) were purchased from Cell
17
Biolabs Inc (San Diego, CA). For overexpression studies, SH-SY5Y Cells were plated
18
in 6 well dishes. The virus was added directly to the cells at a final concentration of
19
108 PFU/ml and allowed to incubate for an additional 24 hours, and then treated as
20
described above. Fyn shRNA, GSK-3β shRNA, and Nrf2 shRNA were purchased
21
from Santa Cruz Biotechnology. For gene knockdown studies, SH-SY5Y Cells were
22
transfected with short hairpin RNA (shRNA) plasmid as indicated using FuGENE® 6
23
Transfection Reagent obtained from Promega (Madison, WI) according to the
24
manufacturer’s protocol, allowed to incubate for 24 h, and then treated as described
25
above. Control shRNA Plasmid-A (Santa Cruz Biotechnology, Santa Cruz, CA) was 22
ACS Paragon Plus Environment
Page 22 of 54
Page 23 of 54
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
1
used as a negative control. Knockdown efficiency of ~70% was observed with
2
Dominant Negative mutation or shRNA plasmid, as determined by western blot.
3 4
Statistical analysis
5 6
Data in bar graphs represent means (SD) and means were obtained from average data
7
of at least three independent experiments, if not otherwise stated. An analysis of
8
variance (ANOVA) followed by post hoc Student-Newman-Keuls (SNK) test was
9
carried out for multiple comparisons using SSPS software. Statistical significance was
10
accepted for P values < 0.05.
11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 23
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1 2
ASSOCIATED CONTENT
3 4
Supporting Information
5
Result from ELISA BrdU assay (Table S1 and Figure S1), MTS assay (Table S2 and
6
Figure S2), MTS assay (Figure S3), SOD activity assay (Figure S4), ELISA-based
7
TransAM™ Nrf2 assay (Figure S5), and Western blotting analyses for Akt
8
phosphorylation (Figure S6).
9 10 11
This material is available via the Internet at http://pubs.acs.org.
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 24
ACS Paragon Plus Environment
Page 24 of 54
Page 25 of 54
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
1
AUTHOR INFORMATION
2 3
Corresponding author
4 5
* E-mail address:
[email protected] 6 7
Author Contributions
8 9
Miaoxian Dong and Xiaojie Zhang designed the study, and supervised the study.
10
Qiang Li and Miaoxian Dong carried out experiments. Miaoxian Dong and Chengu
11
Niu undertook the statistical analysis, and wrote the first draft of the manuscript.
12 13
Funding
14 15
This work was supported by the National Natural Science Foundation of China grant
16
81373629 awarded to Miaoxian Dong.
17 18
Notes
19 20
The authors declare that they have no conflict of interest.
21 22 23 24 25
25
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
ACKNOWLEDGMENTS
2 3
We thank Dr. Yingcai Niu for critical comments on the manuscript and Xiaoming Li
4
for secretarial help.
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
26
ACS Paragon Plus Environment
Page 26 of 54
Page 27 of 54
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
1
REFERENCES
2 3
1.
De Virgilio, A., Greco, A., Fabbrini, G., Inghilleri, M., Rizzo, M.I., Gallo, A.,
4
Conte, M., Rosato, C., Ciniglio Appiani, M., de Vincentiis, M. (2016)
5
Parkinson's disease: Autoimmunity and neuroinflammation. Autoimmun. Rev. 15,
6
1005-1011.
7
2.
Faulkner, M.A. (2014) Safety overview of FDA-approved medications for the
8
treatment of the motor symptoms of Parkinson's disease. Expert. Opin. Drug Saf.
9
13, 1055-1069.
10
3.
Acosta-Cabronero, J., Cardenas-Blanco, A., Betts, M.J., Butryn, M.,
11
Valdes-Herrera, J.P., Galazky, I., Nestor P.J. (2017) The whole-brain pattern of
12
magnetic susceptibility perturbations in Parkinson's disease. Brain 140,
13
118-131.
14
4.
Lindholm, D., Mäkelä, J., Di Liberto, V., Mudò, G., Belluardo, N., Eriksson, O.,
15
Saarma, M. (2016) Current disease modifying approaches to treat Parkinson's
16
disease. Cell Mol. Life Sci. 73, 1365-1379.
17
5.
Filograna, R., Beltramini, M., Bubacco, L., Bisaglia, M. (2016) Anti-Oxidants
18
in Parkinson's Disease Therapy: A Critical Point of View. Curr. Neuropharmacol.
19
14, 260-271.
20
6.
Kalinderi, K., Bostantjopoulou, S., Fidani, L. (2016) The genetic background of
21
Parkinson's disease: current progress and future prospects. Acta. Neurol. Scand
22
134, 314-326.
23
7.
Stress Markers in Parkinson's Disease. Clin. Lab. 62, 105-112.
24 25
Bolner, A., Micciolo, R., Bosello, O., Nordera, G.P. (2016) A Panel of Oxidative
8.
Zuo, L., Motherwell, M.S. (2013) The impact of reactive oxygen species and 27
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
genetic mitochondrial mutations in Parkinson's disease. Gene Dec. 532, 18-23.
1 2
9.
Sarrafchi, A., Bahmani, M., Shirzad, H., Rafieian-Kopaei, M. (2016) Oxidative
3
stress and Parkinson's disease: New hopes in treatment with herbal antioxidants.
4
Curr. Pharm. Des. 22, 238-246.
5
10.
Li, C., Pan, Z., Xu, T., Zhang, C., Wu, Q., Niu, Y. (2014) Puerarin induces the
6
upregulation of glutathione levels and nuclear translocation of Nrf2 through
7
PI3K/Akt/GSK-3β signaling events in PC12 cells exposed to lead. Neurotoxicol.
8
Teratol. 46, 1-9.
9
11.
Parkinsonian phenotype by Nrf2. Neurotoxicology 27, 1094-1100.
10 11
Burton, N.C., Kensler, T.W., Guilarte, T.R. (2006) In vivo modulation of the
12.
Liu, H., Yu, C., Xu, T., Zhang, X., Dong, M. (2016) Synergistic protective effect
12
of paeoniflorin and β-ecdysterone against rotenone-induced neurotoxicity in
13
PC12 cells. Apoptosis 21, 1354-1365.
14
13.
Long, L., Cai, X., Guo, R., Wang, P., Wu, L., Yin, T., Liao, S., Lu, Z. (2017)
15
Treatment of Parkinson's disease in rats by Nrf2 transfection using MRI-guided
16
focused ultrasound delivery of nanomicrobubbles. Biochem. Biophys. Res.
17
Commun. 482, 75-80.
18
14.
Wang, X., Wu, H., Chen, H., Liu, R., Liu, J., Zhang, T., Yu, W., Hai, C. (2012)
19
Does insulin bolster antioxidant defenses via the extracellular signal-regulated
20
kinases-protein kinase B-nuclear factor erythroid 2 p45-related factor 2 pathway?
21
Antioxid. Redox Signal 16, 1061-1070.
22
15.
Yu, C.L., Zhao, X.M., Niu, Y.C. (2016) Ferulic Acid Protects Against Lead
23
Acetate-Induced Inhibition of Neurite Outgrowth by Upregulating HO-1 in
24
PC12 Cells: Involvement of ERK1/2-Nrf2 Pathway. Mol. Neurobiol. 53,
25
6489-6500. 28
ACS Paragon Plus Environment
Page 28 of 54
Page 29 of 54
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
1
16.
Free Radic. Biol Med. 66:36-44
2 3
Niture, S.K., Khatri, R., Jaiswal, A.K. (2014) Regulation of Nrf2-an update.
17.
Jain, A.K., Jaiswal, A.K. (2007) GSK-3beta acts upstream of Fyn kinase in
4
regulation of nuclear export and degradation of NF-E2 related factor 2. J. Biol.
5
Chem. 282, 16502-16510.
6
18.
Itokawa, H., Morris-Natschke, S.L., Akiyama, T., Lee, K.H. (2008)
7
Plant-derived natural product research aimed at new drug discovery. J. Nat. Med.
8
62, 263-280.
9
19.
Wang, X.L., Xing, G.H., Hong, B., Li, X.M., Zou, Y., Zhang, X.J., Dong, M.X.
10
(2014) Gastrodin prevents motor deficits and oxidative stress in the MPTP
11
mouse model of Parkinson's disease: involvement of ERK1/2-Nrf2 signaling
12
pathway. Life Sci. 114, 77-85.
13
20.
the treatment of synucleinopathies? Mov. Disord. 31, 225-234.
14 15
Valera, E, Masliah E (2016) Combination therapies: The next logical Step for
21.
Zhao, X., Zou, Y., Xu, H., Fan, L., Guo, H., Li, X., Li, G., Zhang, X., Dong, M.
16
(2012) Gastrodin protect primary cultured rat hippocampal neurons against
17
amyloid-beta peptide-induced neurotoxicity via ERK1/2-Nrf2 pathway. Brain
18
Res. 1482, 13-21.
19
22.
Li, X.M., Zhang, X.J., Dong, M.X. (2017) Isorhynchophylline Attenuates
20
MPP+-Induced Apoptosis Through Endoplasmic Reticulum Stress- and
21
Mitochondria-Dependent Pathways in PC12 Cells: Involvement of Antioxidant
22
Activity. Neuromol Med. doi: 10.1007/s12017-017-8462-x
23
23.
Ho, S.C., Ho, Y.F., Lai, T.H., Liu, T.H., Su, S.Y., Wu, R.Y. (2008) Effect of
24
Tianma Gouteng Decoction with subtractive ingredients and its active
25
constituents on memory acquisition. Am. J. Chin. Med. 36, 593-602. 29
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
24.
Liu, J., Mori, A. (1992) Antioxidant and free radical scavenging activities of
2
Gastrodia
3
Neuropharmacology 31, 1287-1298.
4
25.
Page 30 of 54
elata
Bl.
and
Uncaria
rhynchophylla
(Miq.)
Jacks.
Jia, Y., Shen, J., Li, X., Xie, H., Wang, J., Luo, J., Wang, K.D., Liu, Q., Kong,
5
L. (2014) Identification and analysis of gastrodin and its five metabolites using
6
ultra-fast liquid chromatography electrospray ionization tandem mass
7
spectrometry to investigate influence of multiple-dose and food. J. Chromatogr.
8
A 1358, 110-116.
9
26.
rats detected by LC-MS. J. Pharm. Pharm. Sci. 13, 27-37.
10 11
Wang, W., Ma, C.M., Hattori, M. (2010) Metabolism of isorhynchophylline in
27.
Van der Schyf, C.J. (2015) Rational drug discovery design approaches for treating Parkinson's disease. Expert Opin. Drug Discov. 10, 713-741.
12 13
28. Lu, J.H., Tan, J.Q., Durairajan, S.S., Liu, L.F., Zhang, Z.H., Ma, L., Shen, H.M.,
14
Chan, H.Y., Li, M. (2012) Isorhynchophylline, a natural alkaloid, promotes the
15
degradation of alpha-synuclein in neuronal cells via inducing autophagy.
16
Autophagy 8, 98-108.
17
29.
Jiang, G., Hu, Y., Liu, L., Cai, J., Peng, C., Li, Q. (2014) Gastrodin protects
18
against MPP(+)-induced oxidative stress by up regulates heme oxygenase-1
19
expression through p38 MAPK/Nrf2 pathway in human dopaminergic cells.
20
Neurochem. Int. 75, 79-88.
21
30.
Škrovánková, S., Mišurcová, L., Machů, L. (2012) Antioxidant activity and
22
protecting health effects of common medicinal plants. Adv. Food. Nutr. Res. 67,
23
75-139.
24 25
31.
Sechi, M., Syed, D.N., Pala, N., Mariani, A., Marceddu, S., Brunetti, A., Mukhtar, H., Sanna, V. (2016) Nanoencapsulation of dietary flavonoid fisetin: 30
ACS Paragon Plus Environment
Page 31 of 54
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
1
Formulation and in vitro antioxidant and α-glucosidase inhibition activities.
2
Mater. Sci. Eng. C Mater. Biol. Appl. 68, 594-602.
3
32.
Pedrajas, J.R., McDonagh, B., Hernández-Torres, F., Miranda-Vizuete, A.,
4
González-Ojeda, R., Martínez-Galisteo, E., Padilla, C.A., Bárcena, J.A. (2016)
5
Glutathione Is the Resolving Thiol for Thioredoxin Peroxidase Activity of
6
1-Cys Peroxiredoxin Without Being Consumed During the Catalytic Cycle.
7
Antioxid. Redox. Signal 24, 115-128.
8
33. Smeyne, M, Smeyne RJ (2013) Glutathione metabolism and Parkinson's disease.
Free Radic. Biol. Med. 62, 13-25.
9 10
34.
Liang, L.P., Kavanagh, T.J., Patel, M. (2013) Glutathione deficiency in Gclm
11
null mice results in complex I inhibition and dopamine depletion following
12
paraquat administration. Toxicol. Sci. 134, 366-373.
13
35.
Englert, C., Trützschler, A.K., Raasch, M., Bus, T., Borchers, P., Mosig, A.S.,
14
Traeger, A., Schubert, U.S. (2016) Crossing the blood-brain barrier:
15
Glutathione-conjugated poly(ethylene imine) for gene delivery. J. Control.
16
Release 241, 1-14.
17
36.
Liu, Y., Ma, H., Zhang, L., Cui, Y., Liu, X., Fang, J. (2016) A small molecule
18
probe reveals declined mitochondrial thioredoxin reductase activity in a
19
Parkinson's disease model. Chem. Commun (Camb) 52, 2296-2299.
20
37.
thioredoxin system in control of cell fate. Arch. Biochem. Biophys 617, 101-105.
21 22
Matsuzawa, A. (2017) Thioredoxin and redox signaling: Roles of the
38.
Liu, Z., Jing, Y., Yin, J., Mu, J., Yao, T., Gao, L. (2013) Downregulation of
23
thioredoxin reductase 1 expression in the substantia nigra pars compacta of
24
Parkinson's disease mice. Neural. Regen. Res. 8, 3275-3283.
25
39.
Zhao, J., Shukla, S.J., Xia, M. (2016) Cell-Based Assay for Identifying the 31
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
Modulators of Antioxidant Response Element Signaling Pathway. Methods Mol.
2
Biol. 1473, 55-62.
3
40.
Chapple, S.J., Keeley, T.P., Mastronicola, D., Arno, M., Vizcay-Barrena, G.,
4
Fleck, R., Siow, R.C., Mann, G.E. (2016) Bach1 differentially regulates distinct
5
Nrf2-dependent genes in human venous and coronary artery endothelial cells
6
adapted to physiological oxygen levels. Free Radic. Biol. Med. 92, 152-162.
7
41.
Iso, T., Suzuki, T., Baird, L., Yamamoto, M. (2016) Absolute Amounts and
8
Status of the Nrf2-Keap1-Cul3 Complex within Cells. Mol. Cell Biol. 36,
9
3100-3112.
10
42.
Surh, Y.J., Kundu, J.K., Na, H.K. (2008) Nrf2 as a master redox switch in
11
turning on the cellular signaling involved in the induction of cytoprotective
12
genes by some chemopreventive phytochemicals. Planta. Med. 74, 1526-1539.
13
43
Zenkov, N.K., Kozhin, P.M., Chechushkov, A.V., Martinovich, G.G.,
14
Kandalintseva, N.V., Menshchikova, E.B. (2017) Mazes of Nrf2 Regulation.
15
Biochemistry (Mosc). 82, 556-564.
16
44
Li, R., Zhang, L.M., Sun, W.B. (2017) Erythropoietin rescues primary rat
17
cortical neurons from pyroptosis and apoptosis via Erk1/2-Nrf2/Bach1 signal
18
pathway. Brain Res. Bull. 130, 236-244.
19
45
Kanzaki, H., Shinohara, F., Itohiya, K., Yamaguchi, Y., Katsumata, Y.,
20
Matsuzawa, M., Fukaya, S., Miyamoto, Y., Wada, S., Nakamura, Y. (2017)
21
RANKL induces Bach1 nuclear import and attenuates Nrf2-mediated
22
antioxidant enzymes, thereby augmenting intracellular reactive oxygen species
23
signaling and osteoclastogenesis in mice. FASEB. J. 31, 781-792.
24 25
46.
Mathur, A., Rizvi, F., Kakkar, P. (2016) PHLPP2 down regulation influences nuclear Nrf2 stability via Akt-1/Gsk3β/Fyn kinase axis in acetaminophen 32
ACS Paragon Plus Environment
Page 32 of 54
Page 33 of 54
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
1
induced oxidative renal toxicity: Protection accorded by morin. Food Chem.
2
Toxicol. 89, 19-31.
3
47.
survival. Toxicol. Appl. Pharmacol. 244, 37-42.
4 5
Niture, S.K., Kaspar, J.W., Shen, J., Jaiswal, A.K. (2010) Nrf2 signaling and cell
48.
Cheng, Y., Zhang, J., Guo, W., Li, F., Sun, W., Chen, J., Zhang, C., Lu, X., Tan,
6
Y., Feng, W., Fu, Y., Liu, G.C., Xu, Z., Cai, L. (2016) Up-regulation of Nrf2 is
7
involved in FGF21-mediated fenofibrate protection against type 1 diabetic
8
nephropathy. Free Radic. Biol. Med. 93, 94-109.
9
49.
Kato, A., Naiki-Ito, A., Nakazawa, T., Hayashi, K., Naitoh, I., Miyabe, K.,
10
Shimizu, S., Kondo, H., Nishi, Y., Yoshida, M., Umemura, S., Hori, Y., Mori, T.,
11
Tsutsumi, M., Kuno, T., Suzuki, S., Kato, H., Ohara, H., Joh, T., Takahashi, S.
12
(2015) Chemopreventive effect of resveratrol and apocynin on pancreatic
13
carcinogenesis via modulation of nuclear phosphorylated GSK3β and ERK1/2.
14
Oncotarget. 6, 42963-42975.
15
50
Redox. Biol. 10, 191-199.
16 17
Done, A.J., Traustadóttir, T. (2016) Nrf2 mediates redox adaptations to exercise.
51
Ramalingam, M., Kim, S.J. (2016) The Neuroprotective Role of Insulin Against
18
MPP(+) -Induced Parkinson's Disease in Differentiated SH-SY5Y Cells. J. Cell
19
Biochem. 117, 917-26.
20 21 22 23 24 25
33
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
Table 1
2
exposed to MPP+
Page 34 of 54
Combination index for GAS and IRN on cell viability in SH-SY5Y cells
3
GAS (µM)
IRN (µM)
CI
Fa
Description
0.25
0.075
1.205
0.368
Antagonism
0.5
0.15
0.705
0.414
Synergism
1.0
0.3
0.614
0.447
Synergism
2.0
0.6
0.685
0.471
Synergism
4.0
1.2
0.830
0.492
Synergism
4
Data was analyzed using CompuSyn software. Interpretation of CI values: CI < 0.9
5
means synergism; CI = 0.9 – 1.1 means additive; CI > 1.1 means antagonism. CI,
6
combination index; Fa, fraction affected (that is, absorbance)
7 8 9 10 11 12 13 14 15 16 17 18 19
34
ACS Paragon Plus Environment
Page 35 of 54
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Neuroscience
1
FIGURE LEGENDS
2 3
Figure 1
4 5
IRN in combination with GAS exerts synergetic neuroprotection against MPP+
6
toxicity through a Nrf2-regulated antioxidant mechanisms. SH-SY5Y cells were
7
treated with varying concentrations of IRN and GAS at a fixed ratio (3:10) for 1 h
8
prior to the challenge with MPP+ at 500 µM for additional 24 h. A, cell viability was
9
evaluated by MTS assay. B, after 24 h of transfection with Nrf2 shRNA, SH-SY5Y
10
cells were treated with IRN and/or GAS. Cell viability was evaluated by MTS assay.
11
C, SH-SY5Y cells were treated with IRN and/or GAS, and intracellular ROS
12
generation was assessed by the DCFH-DA method. D, lipid hydroperoxide was
13
assessed by utilizing the redox reactions with ferrous ions. All values are expressed as
14
means ± SD, n = 3; *, p < 0.05 vs. control; §, p < 0.05 vs. MPP+ challenge; ∫, p < 0.05
15
vs. GAS or IRN alone.
16 17
Figure 2
18 19
GAS/IRN enhances GSH system in MPP+-challenged SH-SY5Y cells. A,
20
SH-SY5Y cells were treated with IRN and/or GAS followed by challenge with MPP+
21
for 24 h. GSH and GSSG levels were assessed by fluorometric techniques. B, protein
22
expression of GCLc and GCLm were analyzed by western blot using indicated
23
antibodies. GAPDH served as loading controls. C, bar graph shows quantification of
24
GCLc and GCLm normalized to GAPDH. D, total RNA was extracted by the Trizol
25
method, and the levels of GCLc and GCLm mRNAs were determined by real-time 35
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1
RT-PCR, normalized by GAPDH. E, GSH-Px activity was determined using the
2
spectrophotometric method. All values are expressed as means ± SD, n = 3; *, p